JNJNYSEChecked

What is Johnson & Johnson tied to?

Johnson & Johnson sells prescription medicines, such as Darzalex for blood cancer and Tremfya, and medical devices for heart, eye and joint care. Medicines were $16.8 billion of its $25.4 billion of sales in the third quarter of 2026. It plans to spin off its joint and bone business as a separate company called DePuy Synthes.

Biggest ties: Genmab (licensed it Darzalex); Legend Biotech (Carvykti partner); Patients and drug plans (Innovative Medicine)

The map

Suppliers sit above Johnson & Johnson, customers below. Tap a box, or step through with the arrows.

J&J depends on1 of 7

Genmab

Size$4.24 billion of Darzalex sales (Q3 2026)

Genmab, a Danish biotech, gave J&J the worldwide rights to the cancer drug Darzalex and receives royalties on its sales. Darzalex sold $4.24 billion in the third quarter of 2026.

What to watch: Darzalex sales growth.

Boxes with a corner arrow have their own map. Sizes show where a source gives one.

Outside forces

Things Johnson & Johnson can't control that affect its business. Tap one to see what to watch.

Talc lawsuitsIn July 2026 J&J proposed paying $5.5 billion to settle about 76,000 lawsuits claiming its talc powder caused ovarian cancer. The deal needs at least 95% of claimants to join, and a one-time charge for it cut third-quarter earnings.What to watch

Whether enough claimants sign on.

Sources: Bloomberg Law: J&J to pay $5.5 billion to settle talc claims; AP via ABC News: J&J proposes $5.5 billion talc settlement; Johnson & Johnson: Q3 2026 results (SEC)Checked

Orthopaedics spin-offJ&J plans to make its joint replacement and trauma business a separate company called DePuy Synthes, announced in October 2025 for completion within 18 to 24 months.What to watch

The date and terms of the split.

Sources: Johnson & Johnson: intent to separate its orthopaedics business; MedTech Dive: J&J plans to spin out orthopedicsChecked

Stelara copiesStelara faces copies known as biosimilars. Its sales fell 41% to $6.1 billion in 2025, and the decline cut third-quarter 2026 growth by about 6.9 points.What to watch

How fast newer drugs such as Tremfya and Icotyde fill the gap.

Sources: Benzinga: J&J Q3 2026 results; Zacks: J&J Q3 2026 results; Futu: J&J 2025 10-K summaryChecked

Latest earnings

Q3 2026, quarter to Sep 27, 2026

Reported Oct 13, 2026Next report date not announced yet

Revenue

$25.40B

Up 6% from $23.99B a year earlier

Earnings per share

$0.09

Down 96% from $2.12 a year earlier

Lowered by a one-time charge for the proposed talc settlement and by the Firefly Bio and Sail Biomedicines deals.

Sales, last four quartersIn billions of dollars. The last bar is the quarter above.
  1. $24.56BOct–Dec
    2025
  2. $24.06BJan–Mar
    2026
  3. $25.31BApr–Jun
    2026
  4. $25.40BJul–Sep
    2026

Source: Stock Analysis: JNJ quarterly income statementChecked

Company outlook: J&J expects 2026 sales of $101.0 billion to $101.4 billion.

Ties to the map: Medicines from partners on the map, Darzalex and Carvykti, drove growth while devices grew 2.5%.

Compared with the same quarter a year earlier, as reported by the company.

Sources: Johnson & Johnson: Q3 2026 results (SEC); Johnson & Johnson: Q3 2026 results

Where the money comes from

Share of Johnson & Johnson's sales by business and region. Third quarter of 2026, as reported by the company.

By business

  • Innovative Medicine66%$16.76B
  • MedTech34%$8.64B

By region

  • United States59%$14.96B
  • Outside the US41%$10.44B

Source: Johnson & Johnson: Q3 2026 results (SEC)Checked

Competes with

More in Drugmakers

Common questions

Why did J&J's earnings per share drop to $0.09?

A one-time charge for the proposed talc settlement, plus costs from buying Firefly Bio and the Sail Biomedicines deal, in the third quarter of 2026. Earnings were $2.12 a share a year earlier.

What is DePuy Synthes?

J&J's orthopaedics business, which makes hip, knee and other implants. J&J plans to spin it off as a separate company.

Does J&J own Darzalex?

J&J sells it under a worldwide license from Genmab, which receives royalties on the sales.

Read every connection

All 7 connections as cards, with sources. It's the same detail you get by tapping a box on the map.
Show allHide

Suppliers

The companies Johnson & Johnson relies on to make what it sells, with sources.

Customers

Who buys from Johnson & Johnson or pays it, with sources.

Patients and drug plans

Innovative Medicine

Size$16.76 billion (Q3 2026)

Medicine sales rose 7.7% to $16.76 billion in the third quarter of 2026, helped by Tremfya, Darzalex and Carvykti. Falling sales of Stelara, which now faces copies, cut growth by about 6.9 points.

What to watch: Stelara's decline against new medicines.

Sources: Johnson & Johnson: Q3 2026 results (SEC); Benzinga: J&J Q3 2026 resultsChecked

About this page

Connections were last checked against company filings and news reports on Nov 21, 2026. Companies don't have to disclose every supplier or customer, so this map shows the most important ones that are publicly known, not every link.

How we check connections. StockTies is for information only. It is not investment advice. Spot something out of date? Tell us.